<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<meta name="apple-mobile-web-app-capable" content="yes">
<meta name="viewport"
	content="width=device-width initial-scale=1, user-scalable=no">
<meta name="apple-mobile-web-app-title" content="AstraZeneca Oncology">
<link rel="stylesheet" href="css/style.css" />
<link rel="stylesheet" href="css/animate.min.css" />
<style type="text/css">
    .explanation {top: 133px; position: relative; line-height:20px; width:100%;}
    .footnote {top: 570px; color: #666767; position: relative; line-height: 14px; width: 100%; font-size: 11px;}
    .cuzick {color:#666767; list-style:none; position:absolute; font-family:'HelveticaNeueLTStd-LtCn';top: 602px; left: 780px; font-size: 10px;}
    .tableheader, table{color:#666767; font-size:18px; top: 203px; position:relative;}
    
    table  {width:100%; top: 217px; position:relative;font-size:12px; line-height:16px;}
    td, th,  
    tr:nth-of-type(4) td:last-of-type,
    tr:nth-of-type(5) td:last-of-type  { border:1px solid; border-collapse: collapse; padding: 15px 10px; text-align: center;vertical-align: middle; height: 15px;}
    td:first-of-type, th, tr:nth-of-type(2) {text-align: left; font-family:'HelveticaNeueLTStd-Bd'; }
    th, tr:nth-of-type(2) {background:#f6f6f6;}
    td:first-of-type, td:last-of-type, th:last-of-type {background: #fff;}
    td:last-of-type, th:last-of-type {border:none;}
    td {min-width: 95px;}
    td:first-of-type {min-width: 160px;width: 160px;}
    tr:nth-of-type(4) td:last-of-type {min-width: 115px;}
    tr:nth-of-type(2) td {min-height: 38px;height: 38px; } 
</style>
</head>
<body class='nolvadex'>
	<div class='container'>
        <div class="content">
	        <h1>Nolvadex for 5 years, reduces the risk of breast cancer for up to 16 years.<sup>1,2*</sup></h1>
	        <div class="explanation">*For women with a lifetime breast cancer risk of 1.5 to 3 times the population average compared to placebo.<sup>1</sup>
Reductions in risk were recorded for invasive ER positive cancers and ductal carcinoma in situ, but not for
invasive ER negative cancers. Median follow up 16 years.<sup>1,2</sup></div>

           <div class="tableheader">Breast cancers according to treatment allocation and follow-up period</div>
           <table>
            <tr><th colspan="5">TOTAL NUMBER OF BREAST CANCERS</th><th></th></tr>
            <tr><td></td><td>Placebo<br/>(n=3575)</td><td>Tamoxifen<br/>(n=3579)</td><td>HR<br/>(95% CI)</td><td>p value</td><td></td></tr>
            <tr><td>Overall</td><td>350</td><td>251</td><td>0.71 (0.60–0.83)</td><td>p&lt;0.0001</td><td></td></tr>
            <tr><td>0–10 year follow-up period</td><td>226</td><td>163</td><td>0.72 (0.59–0.88)</td><td>p=0.0011</td><td rowspan="2">Ratio≥10 years:<br/>0-10 years (95% CI)<br/>0.98 (0.74-1.30)<br/>p=0.91</td></tr>
            <tr><td>≥10 year follow-up period</td><td>124</td><td>88</td><td>0.69 (0.53–0.91)</td><td>p=0.0075</td></tr>
           </table>
		   <span class="cuzick">Adapted from Cuzick J et al, 2015</span>
		</div>
	    
		<span class='logo'></span>
		<div class="glasspane"></div>
		<div class="popup">
			<div class='ref'>
				<p>References:</p>
				<ol>
					<li>Nolvadex Approved Product<br />Information. April 2016.</li>
					<li>Cuzick J et al. <i>Lancet Oncol</i><br />
2015; 16: 67–75.</li>
				</ol>
			</div>
			
		</div>
		<div class='footer'></div> 
		<div class="controls">
            <span class="r"></span>
            <span class="i disabled"></span>
            <span class="p"></span>
        </div>
	</div>
	<script type="text/javascript">
       var idx = 'N02';
    </script>
    <script src="js/jquery-3.1.1.min.js" type="text/javascript" charset="utf-8"></script>
    <script src="js/touchy.js" type="text/javascript" charset="utf-8"></script>
    <script src="js/script.js" type="text/javascript" charset="utf-8"></script>
    <script src="js/variables.js" type="text/javascript" charset="utf-8"></script>
	
</body>
</html>
